Anzeige
Mehr »
Login
Donnerstag, 27.02.2025 Börsentäglich über 12.000 News von 688 internationalen Medien
10-faches Wachstum bis 2030? Warum KI-Aktien jetzt die größten Gewinnchancen bieten!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
162 Leser
Artikel bewerten:
(0)

Wemedoo AG: Across Global Alliance Selects Wemedoo's oomnia as Central Clinical Trial Infrastructure

Finanznachrichten News

Across Global Alliance has partnered with Wemedoo AG to implement oomnia as its centralized clinical trial infrastructure, enhancing efficiency, compliance, and collaboration across its alliance members operating in over 90 countries.

SINGAPORE, Feb. 27, 2025 /PRNewswire/ -- Across Global Alliance, is a strategic alliance of clinical research organizations (CROs) and Specialist Service Providers has selected oomnia®, Wemedoo's advanced clinical trial data management system, as its centralized digital infrastructure. This strategic decision aims to streamline clinical trial management, enhance real-time collaboration among alliance members, and ensure regulatory compliance in over 90 countries.

Wemedoo AG Logo

After an extensive evaluation of available solutions, oomnia emerged as the only system capable of meeting the alliance's complex operational needs. By integrating essential clinical trial functions, including EDC, CTMS, RTSM, and eTMF into a single, unified platform, oomnia eliminates inefficiencies caused by fragmented systems and disjointed data workflows.

"Running global clinical trials requires a system that facilitates seamless collaboration, eliminates unnecessary delays, and ensures data consistency across all sites. With oomnia, we have found a platform that meets these demands while maintaining compliance and operational flexibility," said Steven Bukvic, Chairman of the Across Global Alliance.

With oomnia as its digital backbone, Across Global Alliance ensures that all its clients and members benefit from a system that optimizes clinical trial execution, provides real-time data quality reviews, and is easy to navigate.

"This partnership with Across Global Alliance is another step toward transforming how clinical trials are managed. By providing a truly integrated and adaptive system, we enable alliance members to focus on scientific progress rather than administrative complexity," said Nina Cihoric, CEO of Wemedoo AG.

Contact: Steven Bukvic
Email: bukvics@across.global

For more information visit Wemedoo & Across Global Alliance

About Across Global Alliance

Across Global Alliance is a Singapore-based strategic alliance of globally operating clinical research organizations (CROs) and Specialist Service Providers. Through the integration of regional expertise with a unified operational framework, the alliance provides comprehensive clinical research services across diverse therapeutic areas. With its unified infrastructure, Across Global Alliance enables seamless coordination, data integrity, and operational excellence in global clinical research.

About Wemedoo

Wemedoo AG, a Swiss-based company specializes in healthcare data-driven solutions. By combining advanced technologies with deep clinical expertise, Wemedoo empowers research teams, CROs, and sponsors to conduct clinical trials more efficiently, reduce costs, and accelerate medical innovation.

Logo - https://mma.prnewswire.com/media/2629680/Wemedoo_AG_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/across-global-alliance-selects-wemedoos-oomnia-as-central-clinical-trial-infrastructure-302387819.html

© 2025 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.